Vertex Pharmaceuticals completed the acquisition of the rights to develop and commercialize the drug VX-561 and all cystic fibrosis-related assets from Concert Pharmaceuticals. Vertex paid $192 million for VX-561, of which $160 million was paid in 2017 when the agreement was signed.
Vertex Pharmaceuticals completed the acquisition of the rights to develop and commercialize the drug VX-561 and all cystic fibrosis-related assets from Concert Pharmaceuticals. Vertex paid $192 million for VX-561, of which $160 million was paid in 2017 when the agreement was signed. 
ir.concertpharma.com
English (US) 